A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), particularly semaglutide and liraglutide, have revolutionized the treatment of type 2 diabetes and obesity due to their potent effects on weight loss and glycemic control. However,…
BACKGROUND: Obesity remains a major health challenge globally and in Asia, driving cardio-metabolic disease risks. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and mobile health (mHealth) coaching each demonstrate weight loss efficacy, but r…
People living with type 1 diabetes have significantly increased cardiovascular risk compared with the general population. Traditional risk factors include hypertension, dyslipidaemia, and obesity. However, those with type 1 diabetes contend with trea…
Acquired hypothalamic obesity (aHO) is a disease characterized by rapid, clinically significant, and persistent weight gain resulting from damage to hypothalamic structures. aHO is associated with substantial morbidity, increased mortality, and marke…
PURPOSE OF REVIEW: This article reviews the evidence for cardiovascular and renal risk reduction with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes mellitus (T2DM), based on randomized controlled trials, including emerging…
The introduction of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin agonists targeting both the GIP and GLP-1 receptors (GIP/GLP-1 dual agonists) has reshaped obesity management, approaching degrees of weight loss previously a…
BACKGROUND: Metabolic and bariatric surgery (MBS) is the most effective treatment for severe obesity, producing durable weight loss and improvement in obesity-related comorbidities. However, a subset of patients experience inadequate weight loss (non…
BACKGROUND: Dumping syndrome and reactive hypoglycemia are common complications after bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB). Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a potential therape…
Ulcerative colitis (UC) often requires immunosuppressive therapy for remission. Glucagon-like peptide-1 receptor agonists are used for diabetes and obesity, although their role in UC is unclear. We report a 42-year-old woman with left-sided UC and po…
IMPORTANCE: Consistent results from preclinical and clinical studies indicate that activation of glucagon-like peptide-1 receptors (GLP-1 Rs) affects reward processes; however, to our knowledge, no study has previously evaluated whether a GLP-1 R ago…
AIMS/HYPOTHESIS: Type 2 diabetes is associated with worsened stroke outcome and lasting disability. The underlying mechanisms are undetermined, and no therapy is available. We experimentally investigated whether pharmacologically targeting obesity, w…
BACKGROUND: Obesity remains a major public health concern in the United States, with increasing demand for body-contouring procedures following significant weight loss. Appalachia-a region characterized by limited healthcare access and a high prevale…
AIMS: To characterize switching among GLP-1 receptor agonists (GLP-1 RAs) in a large private-sector cohort in Poland and to quantify therapy- and patient-level associations with switching while accounting for switching opportunity and calendar-time d…
IMPORTANCE: Metabolic dysfunction-associated steatotic liver disease (MASLD) includes a range of liver conditions, progressing from isolated steatosis (characterized by fat accumulation in the liver without inflammation) to metabolic dysfunction-asso…
AIMS/HYPOTHESIS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease globally and is closely associated with type 2 diabetes (T2D) and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1R…